|
Theme | Subthemes |
|
(1) Support for the motive for discontinuation | Approve discontinuation | Support nonfunding and restricted access of OxyNEO | Addiction potential of OxyContin exceeds that of alternate drugs | Sufficient alternate drugs to OxyContin |
(2) Discontinuation insignificantly impacted pain control | Patients attain similar pain relief with alternate medications | Transition to other drugs carried out efficiently | Sufficient alternate drugs to choose from | Unsatisfactory outcome ascribed to medication abuse |
(3) Sufficient resources for opioid prescribing | Appropriate prescribing of opioids results in safe and effective use | Lack of adherence to existing guidelines is the real issue | Narcotic database will enhance monitoring strategies | |
(4) Disapproval of generics | Existing pain medications are adequate | Introduction of generics defeats discontinuation | Physicians do not prescribe generics | Generics drug of choice for addicts |
(5) Barriers and opportunities in optimizing care | Switching to a different medication was successfully accomplished | Exceptional Access Program made it extremely difficult to access OxyNEO | Abruptness of the change with short notice period to change drugs | Delay in notifying professionals and in processing applications for patients to start receiving OxyNEO |
|